Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringDrugs Discovery & Development
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyMedical Devices IndustryMedical ProductsHealthcarePatients
Core Technology
BiologicalsMolecules
Tags (8)
sustained-releasegeneric-drugspharmaceuticalsdrug-discoverynanotechnologypharma-companiesdrug-deliverypatients
Geographic Markets
GermanyUnited KingdomIsraelSingapore
Dexcel Pharma News
1 article
Kitov Pharma signs Dexcel hypertension drug deal
Kitov Pharmaceutical Holdings Ltd. has signed a strategic cooperation agreement with Dexcel Pharma Ltd. to develop and produce its treatment for hypertension, KIT-302. Kitov is preparing a Phase III clinical trial of the drug. Dexcel will develop the drugs final formulation for the filing of a New Drug Application (NDA) with the US Food and Drug Administration (FDA). Kitov will pay Dexcel $2 million in cash and $1.5 million in shares to use the companys facilities.
PartnersInvestment
Dexcel Pharma Team
Ygal Seelenfreund
VP International Sales & Marketing
Employee Info
| Employees (range) | 500+ |
| Exact count | 521 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 14 classification IDs that could be used for matching.